Opella, established in 2014 and headquartered in Paris, France, is the Consumer Healthcare business unit of Sanofi. Operating in 43 countries and distributing products in over 140 countries, Opella has positioned itself as a leading fast-moving consumer healthcare company. The company’s portfolio includes well-known brands such as Doliprane, Mucosolvan, Allegra, and Buscopan, addressing various health needs in the self-care market.
Opella is committed to ethical practices and sustainability. The company has achieved B Corp certification in regions including North America, Italy, Germany, Hispanic Latin America, and Western Europe (excluding France), reflecting its dedication to social and environmental performance. Additionally, Opella emphasizes human rights, ethical conduct, and provides confidential reporting channels to uphold integrity within its operations.
With a workforce of approximately 11,000 employees globally, Opella continues to focus on consumer-centric strategies, leveraging digital and data innovations to drive sustainable business growth and maintain its leadership in the consumer healthcare sector.
